Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

A Phase 2 trial of PF-06252616 in Duchenne Muscular Dystrophy was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PF-06252616

Snippet

Sponsor: Pfizer | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2019-07-23